AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Schizophrenia: Olanzapine is effective in managing the symptoms of schizophrenia, including hallucinations, delusions, disorganized thinking, and emotional disturbances. It helps stabilize mood and improve overall functioning in individuals with this condition.
Management of Bipolar Disorder: Olanzapine is used in combination with other medications to treat acute manic or mixed episodes associated with bipolar disorder. It can help control symptoms such as elevated mood, agitation, irritability, and impulsivity.
Maintenance Therapy for Bipolar Disorder: Olanzapine may also be prescribed as a maintenance treatment to prevent recurrence of manic or mixed episodes in patients with bipolar disorder.
Agitation and Aggression: Olanzapine can be used to manage agitation and aggression in various psychiatric conditions, including schizophrenia and bipolar disorder. It helps to calm patients and reduce the risk of harm to themselves or others.
Anxiety Disorders: Olanzapine may be prescribed off-label for the treatment of anxiety disorders, particularly when other medications have been ineffective. It can help alleviate symptoms of anxiety and promote relaxation in some individuals.
Augmentation Therapy: Olanzapine is sometimes used as an augmentation strategy in the treatment of depression, especially in cases where standard antidepressants have not provided sufficient relief. It may help improve mood and reduce symptoms of depression when combined with other medications.
Sleep Disorders: Olanzapine can be prescribed off-label to manage sleep disturbances, particularly in individuals with psychiatric disorders such as schizophrenia or bipolar disorder. It may help improve sleep quality and duration in some patients.
Tourette Syndrome: Olanzapine may be used off-label to manage tics and behavioral symptoms associated with Tourette syndrome, a neurological disorder characterized by involuntary movements and vocalizations.
Side Effects: Common side effects of olanzapine may include drowsiness, weight gain, increased appetite, dry mouth, constipation, dizziness, and orthostatic hypotension (drop in blood pressure upon standing). Long-term use may be associated with metabolic changes, including elevated blood sugar levels and lipid abnormalities.
Rare but Serious Side Effects: Olanzapine may also be associated with rare but serious side effects such as neuroleptic malignant syndrome (NMS), tardive dyskinesia (involuntary movements), and agranulocytosis (severe reduction in white blood cell count). Patients should be monitored regularly for these potential complications.
Pregnancy and Breastfeeding: Olanzapine should be used with caution during pregnancy and breastfeeding, as its safety in these situations is not well-established. The potential risks and benefits should be carefully weighed by healthcare providers when considering its use in pregnant or breastfeeding women.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Lactobacillus acidophilus | Increases |
species | Lactobacillus crispatus | Increases |
species | Lactobacillus gasseri | Increases |
species | Lactobacillus helveticus | Increases |
species | Lactobacillus jensenii | Increases |
species | Lactobacillus johnsonii | Increases |
species | Lactobacillus kefiranofaciens | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.6 | 0.6 | |
ADHD | 0.9 | 0.2 | 3.5 |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | |
Allergies | 1.1 | 0.3 | 2.67 |
Allergy to milk products | 0 | 0 | |
Alzheimer's disease | 0.5 | 1 | -1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.9 | -0.8 |
Ankylosing spondylitis | 0.6 | 0 | 0 |
Anorexia Nervosa | 0.4 | -0.4 | |
Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
Asthma | 0.8 | 0.5 | 0.6 |
Atherosclerosis | 0.8 | -0.8 | |
Atrial fibrillation | 0.4 | 0.6 | -0.5 |
Autism | 1.6 | 2.1 | -0.31 |
Bipolar Disorder | 0 | 0.3 | 0 |
Brain Trauma | 0.6 | 0.1 | 5 |
Carcinoma | 0.3 | 0 | 0 |
Celiac Disease | 0 | 0.8 | 0 |
Cerebral Palsy | 0.1 | 0.1 | 0 |
Chronic Fatigue Syndrome | 1.4 | 0 | 0 |
Chronic Kidney Disease | 0.9 | 0.7 | 0.29 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0 | |
Chronic Urticaria (Hives) | 0.3 | -0.3 | |
Coagulation / Micro clot triggering bacteria | 0 | 0 | |
Colorectal Cancer | 0.1 | 0.9 | -8 |
Constipation | 0.1 | 0 | 0 |
Coronary artery disease | 0.3 | 0.3 | |
COVID-19 | 1.8 | 2.6 | -0.44 |
Crohn's Disease | 1 | 1.5 | -0.5 |
cystic fibrosis | 0.1 | -0.1 | |
deep vein thrombosis | 0 | 0 | |
Depression | 2.3 | 2.7 | -0.17 |
Eczema | 0.3 | 0.3 | |
Endometriosis | 0.9 | 0 | 0 |
Epilepsy | 0.8 | 0.5 | 0.6 |
Fibromyalgia | 0.9 | 0 | 0 |
Functional constipation / chronic idiopathic constipation | 0.7 | 0.1 | 6 |
gallstone disease (gsd) | 0.3 | -0.3 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.6 | |
Generalized anxiety disorder | 0 | 0 | |
Graves' disease | 0 | 0.6 | 0 |
Halitosis | 0 | 0 | |
Hashimoto's thyroiditis | 0.5 | 0 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 1.1 | -1.75 |
hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
hyperglycemia | 0.6 | 0.5 | 0.2 |
Hyperlipidemia (High Blood Fats) | 1 | 1 | |
hypertension (High Blood Pressure | 0.8 | 0.8 | 0 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.2 | 0.6 | -2 |
IgA nephropathy (IgAN) | 0.6 | 0 | 0 |
Inflammatory Bowel Disease | 1.1 | 2.1 | -0.91 |
Insomnia | 0 | 0.9 | 0 |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 0.9 | 1 | -0.11 |
Liver Cirrhosis | 0.8 | 0.8 | 0 |
Long COVID | 1.6 | 1.3 | 0.23 |
Low bone mineral density | 0 | 0 | |
Lung Cancer | 0.3 | -0.3 | |
ME/CFS with IBS | 0 | 0 | |
ME/CFS without IBS | 0.8 | 0 | 0 |
Metabolic Syndrome | 1 | 1.3 | -0.3 |
Mood Disorders | 2.6 | 3.6 | -0.38 |
multiple chemical sensitivity [MCS] | 0.1 | 0.6 | -5 |
Multiple Sclerosis | 1.9 | 1.3 | 0.46 |
Multiple system atrophy (MSA) | 0.4 | 0.6 | -0.5 |
Neuropathy (all types) | 0.1 | 0.6 | -5 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | -1.3 | |
Obesity | 0.2 | 1.1 | -4.5 |
obsessive-compulsive disorder | 0.7 | 0.6 | 0.17 |
Osteoarthritis | 0.3 | 0.3 | |
Osteoporosis | 0.9 | 0.9 | 0 |
Parkinson's Disease | 1.5 | 1.3 | 0.15 |
Polycystic ovary syndrome | 0 | 0.8 | 0 |
Psoriasis | 0.1 | 0.9 | -8 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 1 | 0.3 |
Rosacea | 0.6 | 0 | 0 |
Schizophrenia | 0.6 | 1.2 | -1 |
scoliosis | 0 | 0 | |
Sjögren syndrome | 0.5 | -0.5 | |
Sleep Apnea | 0.3 | -0.3 | |
Stress / posttraumatic stress disorder | 0.2 | 1.4 | -6 |
Systemic Lupus Erythematosus | 1.2 | 0.6 | 1 |
Tic Disorder | 0 | 0 | |
Tourette syndrome | 0.7 | 0 | 0 |
Type 1 Diabetes | 0.6 | 0.1 | 5 |
Type 2 Diabetes | 1 | 1.3 | -0.3 |
Ulcerative colitis | 0 | 1.4 | 0 |
Unhealthy Ageing | 0.5 | 1.4 | -1.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.